Premium
Pityriasis Rosea in a Patient with Behçet's Disease Treated with Interferon Alpha 2A
Author(s) -
Durusoy Çiçek,
Alpsoy Erkan,
Yilmaz Ertan
Publication year - 1999
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1999.tb03461.x
Subject(s) - pityriasis rosea , behcet's disease , dermatology , medicine , alpha interferon , alpha (finance) , interferon , disease , virology , surgery , construct validity , patient satisfaction
Interferons have been used for the treatment of many diseases because of their immunomodulatory, antiviral, antitumoral, and antiproliferative effects. Systemic interferon alpha 2a (IFN‐α2a) is also efficacious in the management of Behçet's disease (BD). Many adverse cutaneous reactions related to IFN‐α have been reported. In the light of the current literature, we report here the first case of Pityriasis rosea (PR) that developed while receiving IFN‐α2a for BD. However, since this is the first report on this association, further observations are needed to determine their clinical relevance.